Glenmark to launch higher strength of FabiFlu for treatment of mild to moderate Covid




Glenmark has also commenced a post-marketing surveillance study on FabiFlu to closely monitor the efficacy and safety of the drug in a large pool of patients prescribed with the oral antiviral Favipiravir, as part of an open label, multicenter, single arm study.



Source link

Leave a Comment

Your email address will not be published.